International Journal of Women's Health

Dovepress
Taylor & Francis Group

Open Access Full Text Article

REVIEW

Characteristics of Gut Microbiota in Patients with Polycystic Ovary Syndrome and Its Association with Metabolic Abnormalities: A Review

Shuang Liu[1], Linqi Cheng[2], Sen Li[3]

[1]The Reproductive Laboratory, Shenyang, People's Republic of China; [2]Department of Biotechnology, Shenyang Medical College, Shenyang, People's Republic of China; [3]The Central Laboratory, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China

Correspondence: Shuang Liu, Email liushuang929@yeah.net

Abstract: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder that has garnered attention in recent years for its intricate relationship with gut microbiota, which plays a significant role in the metabolic abnormalities associated with this condition. This review focuses on the characteristics of gut microbiota in polycystic ovary syndrome (PCOS). By analyzing current literature, we will focus on the alterations in gut microbiota composition, influential factors, and the pathophysiological mechanisms linking gut microbiota and PCOS, diagnostic approaches, therapeutic strategies, as well as controversies and future directions in this field are discussed. Understanding these relationships may provide insights into the disease mechanism and highlight novel treatment strategies for managing PCOS.

Keywords: polycystic ovary syndrome, gut microbiota, metabolic abnormalities, microbiome, endocrine disorders

Introduction

Polycystic Ovary Syndrome (PCOS) is a multifaceted endocrine and metabolic disorder that affects a significant proportion of women of reproductive age. It is characterized by a range of symptoms, including hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Recent research has increasingly focused on the role of gut microbiota in the pathogenesis and progression of PCOS, highlighting its potential influence on metabolic and reproductive health. The gut microbiota, often referred to as the "second genome", plays a critical role in various physiological processes, including metabolism, immune response, and hormonal regulation. Dysbiosis, or an imbalance in gut microbiota, has been implicated in the development of insulin resistance, inflammation, and hormonal dysregulation, which are key features of PCOS.[1]

Studies have shown that women with PCOS often exhibit significant alterations in gut microbiota composition compared to healthy controls. For instance, specific bacterial genera such as Bacteroides and Prevotella have been found to be less abundant in PCOS patients, while other genera, such as Firmicutes and Proteobacteria, may be overrepresented.[2] These changes in microbial diversity and composition can influence the host's metabolic functions, including glucose and lipid metabolism, thereby contributing to the insulin resistance and obesity commonly observed in PCOS.[3] Moreover, the gut microbiota can affect the synthesis and secretion of key hormones, including insulin and androgens, further linking gut health to the clinical manifestations of PCOS.[4] Even among women without polycystic ovary syndrome (PCOS), the gut microbiota can substantially affect their quality of life. Research indicates that metabolites derived from the gut microbiota, such as short-chain fatty acids (SCFAs) and indole-3-propionic acid (IPA), are linked to dietary intake and can influence both metabolic and reproductive health.[5] A cross-sectional study involving 24 women with PCOS and 14 age-matched healthy controls revealed that the PCOS group exhibited a less favorable dietary intake. Furthermore, a significant correlation was observed between gut microbiota composition and dietary glycemic load.[5]

Received: 25 February 2025
Accepted: 14 June 2025
Published: 18 July 2025

The interplay between gut microbiota and metabolic health in PCOS suggests that therapeutic strategies aimed at restoring gut microbiota balance may offer novel interventions for managing the condition. Probiotics, prebiotics, and dietary modifications have shown promise in improving gut microbiota composition and, consequently, metabolic parameters in PCOS patients. For example, the administration of specific probiotic strains has been associated with improved insulin sensitivity and hormonal balance in animal models of PCOS.[6] Additionally, dietary interventions that increase the intake of fiber and polyphenols have been linked to beneficial changes in gut microbiota, which may help alleviate symptoms of PCOS.[3]

Furthermore, fecal microbiota transplantation (FMT) has emerged as a potential therapeutic approach for PCOS, demonstrating the capacity to restore microbial diversity and improve metabolic outcomes.[7] Numerous pre-clinical investigations have employed animal models to explore the effects of fecal microbiota transplantation (FMT). For instance, a study involving germ-free mice that were administered fecal microbiota from either polycystic ovary syndrome (PCOS) patients or healthy individuals revealed that mice receiving microbiota from PCOS patients exhibited distinct bacterial profiles and reproductive endocrine characteristics. These included increased ovarian dysfunction, lipid metabolic disturbances, insulin resistance, and an obesity-like phenotype.[8] This suggests that the gut microbiota from PCOS patients can induce metabolic and reproductive disorders in recipient mice. Conversely, some studies propose that FMT from healthy donors may ameliorate gut dysbiosis and improve associated symptoms. Nonetheless, further research is essential to comprehensively understand the long-term effects, optimal donor selection, and potential risks of FMT, particularly in the context of PCOS-related research, including comparisons with non-PCOS women.The modulation of gut microbiota through lifestyle interventions, such as exercise and stress management, also plays a crucial role in the management of PCOS.[9] Despite the promising findings, further research is essential to elucidate the specific mechanisms by which gut microbiota influences PCOS and to develop targeted therapies that can effectively address the underlying dysbiosis and its associated metabolic disturbances.

In conclusion, the intricate relationship between gut microbiota and PCOS underscores the need for a comprehensive understanding of how microbial health impacts the pathophysiology of this disorder. By targeting gut microbiota through dietary and therapeutic interventions, there is potential for significant improvements in the management of PCOS, ultimately enhancing the quality of life for affected women. Continued exploration in this area will likely yield new insights and treatment avenues that could transform the clinical approach to PCOS and its associated complications.[10]

Basic Concepts and Clinical Manifestations of Polycystic Ovary Syndrome (PCOS)

Definition and Epidemiology of PCOS

Polycystic ovary syndrome (PCOS) is recognized as the most prevalent endocrine disorder among women of reproductive age, affecting approximately 5–17% of this demographic globally.[11] The condition is characterized by a combination of clinical manifestations, including hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Epidemiological studies indicate that PCOS is not only a reproductive concern but also a significant contributor to metabolic disorders, including insulin resistance and type 2 diabetes, which can lead to long-term health complications such as cardiovascular disease.[12] The heterogeneity of PCOS presentations complicates diagnosis and management, as the syndrome can manifest differently across various populations and age groups, necessitating a personalized approach to treatment.[11]

Clinical Manifestations and Diagnostic Criteria

The clinical manifestations of PCOS are diverse and can include irregular menstrual cycles, hirsutism, acne, and obesity, alongside metabolic abnormalities such as insulin resistance.[12] The diagnosis of PCOS typically follows the Rotterdam criteria, which require the presence of at least two of the following three features: oligo- or anovulation, clinical or biochemical signs of hyperandrogenism, and polycystic ovaries observed via ultrasound.[13] However, the diagnostic process can be complicated by overlapping symptoms with other conditions, and the criteria may not adequately address

the metabolic components of the syndrome.[12] Therefore, a comprehensive evaluation that includes hormonal assessments and metabolic profiling is crucial for accurate diagnosis and management.[11]

Metabolic Abnormalities and Their Clinical Significance

Metabolic abnormalities are a hallmark of PCOS, with many affected individuals exhibiting insulin resistance, dyslipidemia, and obesity.[12] These metabolic disturbances not only exacerbate the reproductive symptoms of PCOS but also increase the risk of developing serious long-term health issues, such as type 2 diabetes and cardiovascular disease.[11] Hyperandrogenism is a key characteristic of polycystic ovary syndrome (PCOS) and is intricately associated with metabolic complications, exhibiting variability across different phenotypes. In a study involving 229 women diagnosed with PCOS, an increase in the free androgen index was observed to correlate with elevated levels of triglycerides, total cholesterol, low-density lipoprotein, and the homeostasis model assessment of insulin resistance, while levels of high-density lipoprotein and the quantitative insulin sensitivity check index were found to decrease.[14] Women exhibiting hyperandrogenic PCOS phenotypes frequently demonstrate a higher prevalence of metabolic abnormalities. A meta-analysis examining the relationships between biochemical markers of hyperandrogenism and metabolic parameters in PCOS patients revealed that free testosterone levels were positively correlated with fasting insulin and inversely correlated with high-density lipoprotein cholesterol.[15] Furthermore, hyperandrogenism may interact with additional factors, such as obesity. Women with polycystic ovary syndrome (PCOS) who are obese and exhibit hyperandrogenism are more likely to present with atherogenic lipid profiles compared to their non-obese or non-hyperandrogenic PCOS counterparts.[16] Comprehending these associations is essential for the development of targeted therapeutic strategies tailored to the distinct phenotypes of PCOS, thereby addressing both the reproductive and metabolic dimensions of the syndrome.

In summary, understanding the basic concepts, clinical manifestations, and metabolic implications of PCOS is essential for effective diagnosis and management of this complex syndrome. The integration of reproductive and metabolic health strategies is crucial in addressing the multifaceted challenges posed by PCOS.

Gut Microbiota Composition and Function

Basic Structure and Diversity of Gut Microbiota

The gut microbiota is a complex and dynamic ecosystem composed of trillions of microorganisms, including bacteria, archaea, viruses, and fungi, that inhabit the gastrointestinal tract. This microbial community plays a crucial role in maintaining host health, influencing various physiological processes such as metabolism, immune response, and even behavior. The diversity of gut microbiota is essential for its functionality; a diverse microbiome is associated with better health outcomes, while dysbiosis—a condition characterized by reduced microbial diversity—has been linked to numerous diseases, including obesity, diabetes, and inflammatory bowel disease.[17] Factors such as diet, age, environment, and host genetics significantly influence the composition and diversity of gut microbiota. For instance, a diet rich in fiber promotes the growth of beneficial bacteria, while a high-fat diet can lead to an increase in pathogenic bacteria.[18] Recent studies have shown that the gut microbiota can adapt to changes in the host's diet and lifestyle, highlighting its plasticity and the importance of maintaining a healthy diet for optimal gut health.[19]

Role of Gut Microbiota in Host Metabolism

Gut microbiota plays a pivotal role in host metabolism by breaking down complex carbohydrates that the human body cannot digest on its own, producing short-chain fatty acids (SCFAs) as byproducts. These SCFAs, such as acetate, propionate, and butyrate, are critical for maintaining gut health and regulating metabolic processes, including lipid metabolism and glucose homeostasis.[20] Furthermore, gut microbiota influences the host's energy balance by modulating the absorption of nutrients and the secretion of hormones involved in appetite regulation, such as leptin and ghrelin.[21] Dysbiosis can lead to metabolic disorders, as seen in conditions like obesity and type 2 diabetes, where an imbalance in gut microbiota composition contributes to insulin resistance and inflammation.[22] Thus, understanding the intricate

relationship between gut microbiota and host metabolism is essential for developing strategies to prevent and treat metabolic diseases.

Relationship Between Gut Microbiota and Endocrine Function

The relationship between gut microbiota and endocrine function is a burgeoning area of research, revealing that gut microbes can influence the endocrine system and vice versa. Gut microbiota produces various metabolites that can act as signaling molecules, affecting the secretion of hormones and the function of endocrine organs. For instance, SCFAs produced by gut bacteria have been shown to enhance the secretion of glucagon-like peptide-1 (GLP-1), an important hormone in regulating insulin secretion and appetite.[20] Dysbiosis can disrupt this signaling pathway, leading to metabolic dysfunction and endocrine disorders. Moreover, studies have indicated that certain gut bacteria can modulate the metabolism of hormones such as estrogens and thyroid hormones, impacting overall endocrine health.[21] The bidirectional communication between gut microbiota and the endocrine system underscores the importance of maintaining a balanced microbiome for optimal hormonal health and metabolic function.

In summary, the gut microbiota is a complex ecosystem in the gastrointestinal tract, influencing host health. It affects metabolism by producing SCFAs, regulating nutrient absorption and appetite, and dysbiosis can lead to metabolic disorders. Additionally, it has a bidirectional relationship with the endocrine system, with its metabolites influencing hormone secretion. Maintaining a balanced gut microbiota is crucial for hormonal and metabolic health.

Research Progress on the Gut Microbiota Characteristics of PCOS Patients

Changes in Gut Microbiota Composition

Recent studies have shown that patients with polycystic ovary syndrome (PCOS) exhibit significant alterations in their gut microbiota composition compared to healthy individuals. For instance, a study utilizing 16S rRNA gene sequencing revealed that women with hyperandrogenic PCOS had lower richness and diversity in their gut microbiota compared to controls, indicating a distinct microbial profile associated with this condition.[10] Furthermore, specific bacterial genera such as Bifidobacterium and Enterobacteriaceae_unclassified were found to be more prevalent in PCOS patients, while others like Prevotella showed reduced abundance.[2]

The gut microbiota may exert an influence on polycystic ovary syndrome (PCOS) through various mechanisms. It can modulate metabolic activities, as short-chain fatty acids (SCFAs) produced by the intestinal microbiota are involved in the regulation of insulin resistance, a common characteristic of PCOS.[23] Furthermore, the gut-brain axis, which encompasses the bidirectional communication between the gut microbiota and the central nervous system, may be altered in individuals with PCOS. Certain gamma-aminobutyric acid (GABA)-producing bacteria in the gut have been found to have a positive correlation with serum luteinizing hormone (LH) levels and LH to follicle-stimulating hormone (FSH) ratios in PCOS patients, indicating a potential association between gut microbiota-mediated neuroendocrine changes and PCOS.[24]

The presence of these microbial variations suggests a potential link between gut dysbiosis and the metabolic and hormonal imbalances characteristic of PCOS, highlighting the need for further exploration of how these microbial changes may contribute to the pathophysiology of the syndrome.[4]

Major Changes in Bacterial Species and Their Functions

The gut microbiota of PCOS patients is characterized by notable shifts in specific bacterial species, which may impact various metabolic functions. For example, studies have identified an increase in the relative abundance of bacteria associated with inflammation and metabolic dysfunction, such as Escherichia-Shigella, while beneficial bacteria like Lactobacillus and Bifidobacterium were found to be diminished.[2] These alterations can lead to disrupted metabolic pathways, particularly those related to glucose and lipid metabolism, thereby exacerbating insulin resistance commonly observed in PCOS patients.[25] Additionally, the functional predictions derived from the gut microbiota analyses indicated that pathways related to short-chain fatty acid production, which are crucial for maintaining gut health and metabolic

homeostasis, were significantly altered in PCOS patients, suggesting a potential therapeutic target for managing the syndrome.[26]

The modification of pathways associated with short-chain fatty acids may play a role in the metabolic and hormonal dysregulation observed in polycystic ovary syndrome (PCOS). Specifically, a reduction in bacteria that produce short-chain fatty acids could result in decreased levels of propionate and butyrate, which are crucial for maintaining insulin sensitivity and lipid metabolism.[27] Targeting these pathways presents a potential therapeutic avenue. For example, interventions aimed at increasing the prevalence of short-chain fatty acid-producing bacteria, such as the administration of prebiotics or probiotics, might aid in reestablishing metabolic and hormonal equilibrium in individuals with PCOS. Furthermore, elucidating the precise mechanisms by which these pathways are altered in PCOS could facilitate the development of more targeted pharmacological treatments.

Factors Influencing Changes in Gut Microbiota

Several factors have been identified that influence the composition and diversity of gut microbiota in PCOS patients. Diet is a primary modifiable factor, with studies indicating that dietary patterns can significantly alter gut microbial profiles.[28] For instance, high-fat diets have been shown to promote the growth of pathogenic bacteria while suppressing beneficial strains, thereby contributing to dysbiosis.[10] Additionally, hormonal fluctuations, particularly those related to insulin and androgens, can also impact gut microbiota dynamics, as evidenced by the correlation between serum hormone levels and specific gut microbial taxa.[10] Other environmental factors, such as antibiotic use and lifestyle choices, further complicate the relationship between gut microbiota and PCOS, emphasizing the need for a multifaceted approach to understanding and potentially modulating gut health in this population.[25] Overall, these findings underscore the complex interplay between diet, hormonal status, and gut microbiota composition in the context of PCOS, suggesting that targeted dietary and lifestyle interventions may help restore microbial balance and improve clinical outcomes for affected individuals.

To elucidate the distinctions in intestinal microbiota between individuals with polycystic ovary syndrome (PCOS) and healthy controls, alongside associated metabolic function alterations and influencing factors, the data are systematically summarized in the subsequent table The table reveals significant disparities in the gut microbiota of PCOS patients compared to healthy individuals, which are intricately linked to the metabolic abnormalities characteristic of the condition (Table 1).

In conclusion, individuals with polycystic ovary syndrome (PCOS) exhibit distinct gut microbiota compositions in comparison to healthy controls, characterized by alterations in bacterial richness, diversity, and the prevalence of specific genera. These microbial changes may influence the pathophysiology of PCOS through metabolic and neuroendocrine pathways, potentially contributing to the metabolic and hormonal imbalances associated with the condition.

Gut Microbiota and Metabolic Abnormalities in PCOS

Relationship Between Hyperinsulinemia and Gut Microbiota

Hyperinsulinemia, characterized by elevated insulin levels in the blood, is a hallmark of insulin resistance often seen in PCOS patients. Recent studies suggest that gut microbiota composition may influence insulin sensitivity and secretion. Dysbiosis has been associated with increased intestinal permeability, leading to elevated levels of lipopolysaccharides (LPS) in circulation, which can provoke systemic inflammation and contribute to insulin resistance.[29] Furthermore, specific gut bacteria have been shown to modulate the secretion of incretin hormones, which play a crucial role in insulin regulation. For instance, certain strains of beneficial bacteria can enhance the secretion of glucagon-like peptide-1 (GLP-1), thereby improving insulin sensitivity and reducing hyperinsulinemia.[30] Conversely, an overabundance of pathogenic bacteria can exacerbate insulin resistance, creating a vicious cycle that perpetuates metabolic dysfunction in PCOS patients.[31] Understanding the relationship between gut microbiota and hyperinsulinemia may provide new therapeutic targets for managing insulin resistance in PCOS.

Table 1 Comparative Analysis of Intestinal Flora Characteristics and Metabolic Associations in Patients with Polycystic Ovary Syndrome and Healthy Controls

Comparison Items	Healthy Individuals	Patients with Polycystic Ovary Syndrome (PCOS)
Richness and Diversity of Gut Microbiota	Higher	Lower in some patients (eg, those with hyperandrogenic PCOS)
Abundance of Specific Bacterial Genera	The abundance of genera such as *Bacteroides* and *Prevotella* is relatively stable	The abundance of *Bacteroides* and *Prevotella* decreases; the abundance of *Bifidobacterium, Enterobacteriaceae_unclassified*, etc., increases; the relative abundance of bacteria associated with inflammation and metabolic dysfunction, such as *Escherichia-Shigella*, increases; the abundance of beneficial bacteria such as *Lactobacillus* and *Bifidobacterium* decreases
Short-chain Fatty Acid (SCFA)-related Metabolic Pathways	Normal, playing a positive role in maintaining gut health and metabolic homeostasis	Significantly altered, with a decrease in related bacteria, potentially reducing the production of propionate and butyrate, affecting insulin sensitivity and lipid metabolism
Association with Metabolic Diseases	Normal metabolism, with a lower risk of developing metabolic diseases	Increased risk of metabolic diseases such as insulin resistance, obesity, and type 2 diabetes; gut microbiota dysbiosis may be an important contributing factor
Impact of Diet	A high-fiber diet promotes the growth of beneficial bacteria; a high-fat diet may change the microbiota, but to a relatively lesser extent	The impact of diet is more significant; a high-fat diet easily leads to microbiota dysbiosis, promotes the growth of harmful bacteria, and aggravates metabolic disorders
Impact of Hormones	Hormonal fluctuations have a relatively small impact on the gut microbiota	Fluctuations in hormones such as insulin and androgens significantly affect the dynamics of the gut microbiota and are correlated with specific gut microbial taxa

Interplay Between Obesity and Gut Microbiota

Obesity is another critical metabolic abnormality frequently observed in women with PCOS. The gut microbiota has a profound impact on energy metabolism, fat storage, and appetite regulation. Studies have demonstrated that individuals with obesity often exhibit a distinct gut microbiota composition, characterized by a lower diversity and an increased ratio of Firmicutes to Bacteroidetes.[32] This dysbiosis can lead to increased energy extraction from the diet, thereby promoting weight gain and obesity. In PCOS, the interplay between obesity and gut microbiota is particularly concerning, as excess adipose tissue can further alter microbiota composition, leading to a cycle of inflammation and metabolic dysfunction.[33] Moreover, the inflammatory cytokines released from adipose tissue can negatively affect gut health, exacerbating dysbiosis and contributing to the overall metabolic disturbance in PCOS.[34] Targeting gut microbiota through dietary interventions or probiotics may offer a promising strategy for managing obesity in PCOS patients.

Mechanisms of Inflammatory Response Modulated by Gut Microbiota

Chronic low-grade inflammation is a common feature of PCOS, contributing to its metabolic complications. The gut microbiota plays a crucial role in modulating inflammatory responses through various mechanisms. Dysbiosis can lead to an imbalance in pro-inflammatory and anti-inflammatory cytokines, promoting a state of chronic inflammation.[35] For example, certain gut bacteria can produce short-chain fatty acids (SCFAs), which have anti-inflammatory properties and can help maintain gut barrier integrity. However, an imbalance in gut microbiota can result in reduced SCFA production, leading to increased intestinal permeability and systemic inflammation.[36] Additionally, inflammatory mediators released from the gut can influence the hypothalamic-pituitary-adrenal (HPA) axis, further exacerbating stress-induced inflammation.[37] Understanding the intricate relationship between gut microbiota and inflammatory responses in PCOS may pave the way for novel therapeutic approaches aimed at restoring gut health and alleviating inflammation.

The gut microbiota significantly influences the metabolic abnormalities associated with PCOS, including hyperinsulinemia, obesity, and chronic inflammation. Targeting gut microbiota through dietary modifications, probiotics, or other interventions may provide new avenues for managing these metabolic disturbances in women with PCOS. Further

research is essential to elucidate the specific mechanisms by which gut microbiota affect metabolic health in this population and to develop effective therapeutic strategies.

In conclusion, hyperinsulinemia in polycystic ovary syndrome (PCOS) is influenced by the gut microbiota. Dysbiosis can contribute to insulin resistance by increasing intestinal permeability and lipopolysaccharide (LPS) levels, whereas certain beneficial bacteria may enhance insulin sensitivity. Obesity, which is prevalent in PCOS, exhibits a bidirectional relationship with the gut microbiota. In the context of obesity, gut microbiota dysbiosis promotes weight gain, and in PCOS, excess adipose tissue further disrupts the microbiota, perpetuating a cycle of inflammation and metabolic dysfunction. Chronic low-grade inflammation in PCOS is modulated by the gut microbiota, where dysbiosis disrupts the balance of pro-inflammatory and anti-inflammatory cytokines, reduces the production of short-chain fatty acids (SCFAs), and influences the hypothalamic-pituitary-adrenal (HPA) axis.

Future Research Directions and Clinical Applications

The Potential of Gut Microbiota as a Therapeutic Target

The gut microbiota has emerged as a critical player in various health conditions, particularly in metabolic and endocrine disorders such as polycystic ovary syndrome (PCOS). Dysbiosis, or the imbalance of gut microbiota, is increasingly recognized as a contributing factor to the pathophysiology of PCOS, influencing metabolic processes and hormonal regulation.[38] Recent studies have demonstrated that interventions aimed at restoring gut microbiota balance, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), can ameliorate symptoms associated with PCOS.[39] For instance, the administration of specific probiotics has shown promise in enhancing insulin sensitivity and reducing hyperandrogenism, which are hallmark features of PCOS.[40] Furthermore, the modulation of gut microbiota through dietary interventions, such as increased fiber intake or the consumption of fermented foods, has been linked to improved metabolic health and hormonal balance in affected individuals.[41] These findings underscore the potential of gut microbiota as a therapeutic target, paving the way for innovative treatment strategies that could be tailored to individual patient profiles, thereby enhancing the efficacy of interventions for PCOS and related disorders.[42]

The Prospects of Microbiome Interventions

Microbiome interventions, including the use of probiotics, prebiotics, and dietary modifications, represent a promising frontier in the management of various health conditions, particularly metabolic and endocrine disorders. The gut microbiome's role in modulating immune responses, metabolic pathways, and even psychological states has been increasingly recognized.[43] For example, specific strains of probiotics have been shown to influence the gut-brain axis, potentially alleviating symptoms of anxiety and depression, which are often comorbid with metabolic disorders like PCOS.[44] Additionally, dietary approaches that enhance the diversity and functionality of the gut microbiota, such as the Mediterranean diet rich in fiber and fermented foods, have shown beneficial effects on metabolic health and hormonal balance.[45] These interventions not only aim to restore gut health but also to improve overall well-being by addressing the multifactorial nature of diseases. The integration of microbiome profiling into clinical practice could further refine these interventions, allowing for personalized treatment strategies that consider individual microbiome compositions and their responses to dietary changes.[46]

Individualized Treatment Strategies Based on Microbiome Characteristics

The concept of personalized medicine is gaining traction in the context of gut microbiome research, particularly in developing individualized treatment strategies for metabolic and endocrine disorders. By leveraging advancements in microbiome sequencing technologies, clinicians can obtain detailed insights into a patient's unique microbial composition, which can inform tailored therapeutic approaches.[47] For instance, specific microbial profiles have been associated with varying responses to dietary interventions and pharmacological treatments, suggesting that understanding an individual's microbiome could enhance treatment outcomes.[46] In the case of PCOS, for example, identifying particular gut bacteria linked to insulin resistance or hormonal imbalances can guide the selection of probiotics or dietary modifications that specifically target these issues.[48] Furthermore, the integration of microbiome data with clinical factors

such as genetics, lifestyle, and environmental influences can lead to more comprehensive and effective treatment plans. This personalized approach not only holds promise for improving patient outcomes but also for advancing our understanding of the intricate relationship between the gut microbiome and various health conditions.[49] As research continues to evolve, the potential for microbiome-targeted therapies to revolutionize treatment paradigms in metabolic and endocrine disorders remains substantial.

Elucidating the causal relationship between gut microbiota and polycystic ovary syndrome (PCOS) remains a formidable challenge in contemporary research. The intricate nature of the interaction between gut microbiota and the host, modulated by a multitude of factors such as diet, lifestyle, and genetics, complicates the disentanglement of cause-and-effect relationships. For instance, it remains uncertain whether dysbiosis of the gut microbiota is a primary etiological factor in PCOS or a secondary consequence of the syndrome's hormonal and metabolic alterations. To advance our understanding of the causal mechanisms underlying the gut microbiota-PCOS relationship, longitudinal studies and rigorously designed experimental models are imperative.

In conclusion, the intricate relationship between the gut microbiota and polycystic ovary syndrome (PCOS) highlights a pivotal area of research that has significant implications for both diagnosis and treatment. The distinctive characteristics of gut microbiota in individuals with PCOS play a crucial role in the development of metabolic abnormalities associated with the condition. As we advance our understanding of this connection, it opens up new avenues for early diagnosis and personalized therapeutic strategies tailored to individual patient profiles.

From an expert perspective, it is essential to balance the diverse research findings that underline the complexity of PCOS and its multifactorial nature. Various studies have demonstrated that alterations in gut microbiota composition can influence insulin resistance, inflammation, and hormonal dysregulation, all of which are central to the pathophysiology of PCOS. However, the heterogeneity of the condition itself means that not all patients will exhibit the same microbiota alterations or metabolic outcomes. Therefore, future research should aim to delineate the specific microbial signatures that are most indicative of PCOS and its associated metabolic disturbances.

Moreover, understanding the mechanisms through which the gut microbiota affects PCOS is of paramount importance. This includes investigating the potential role of short-chain fatty acids, bile acids, and other metabolic products generated by gut bacteria. These metabolites may influence systemic inflammation and metabolic health, thereby providing targets for intervention.

In light of these considerations, interdisciplinary collaboration between microbiologists, endocrinologists, and dietitians will be critical in advancing our knowledge. Such collaboration can facilitate the design of targeted interventions, such as dietary modifications or probiotics, that may help restore a healthy gut microbiota and ameliorate the symptoms of PCOS.

Ultimately, a comprehensive understanding of the gut microbiota's influence on PCOS can lead to innovative approaches for prevention and management. By integrating microbiome research into clinical practice, we can enhance our ability to provide individualized care, thereby improving the quality of life for those affected by this complex syndrome. Future studies should focus on longitudinal assessments of gut microbiota changes, their functional implications, and the potential for therapeutic modulation, ensuring that we remain at the forefront of PCOS research and treatment strategies.

Disclosure

All authors report no relevant conflicts of interest in this work.

References

1. Yurtdaş G, Akdevelioğlu Y. A new approach to polycystic ovary syndrome: the gut microbiota. *J Am Coll Nutr*. 2020;39(4):371–382. doi:10.1080/07315724.2019.1657515
2. Yang Y, Cheng J, Liu C, et al. Gut microbiota in women with polycystic ovary syndrome: an individual based analysis of publicly available data. *EClinicalMedicine*. 2024;77:102884. doi:10.1016/j.eclinm.2024.102884
3. Sun Y, Gao S, Ye C, Zhao W. Gut microbiota dysbiosis in polycystic ovary syndrome: mechanisms of progression and clinical applications. *Front Cell Infect Microbiol*. 2023;13:1142041. doi:10.3389/fcimb.2023.1142041

4. Han Q, Wang J, Li W, Chen ZJ, Du Y. Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome. *Microbiome*. 2021;9(1):101. doi:10.1186/s40168-021-01046-5
5. Da Silva TR, Marchesan LB, Rampelotto PH, et al. Gut microbiota and gut-derived metabolites are altered and associated with dietary intake in women with polycystic ovary syndrome. *J Ovarian Res*. 2024;17(1):232. doi:10.1186/s13048-024-01550-w
6. Zhang F, Ma T, Cui P, et al. Diversity of the Gut microbiota in dihydrotestosterone-induced PCOS rats and the pharmacologic effects of diane-35, probiotics, and berberine. *Front Microbiol*. 2019;10:175. doi:10.3389/fmicb.2019.00175
7. Zhou J, Qiu X, Chen X, et al. Comprehensive analysis of gut microbiota alteration in the patients and animal models with polycystic ovary syndrome. *J Microbiol*. 2023;61(9):821–836. doi:10.1007/s12275-023-00079-9
8. Huang F, Deng Y, Zhou M, Tang R, Zhang P, Chen R. Fecal microbiota transplantation from patients with polycystic ovary syndrome induces metabolic disorders and ovarian dysfunction in germ-free mice. *BMC Microbiol*. 2024;24(1):364. doi:10.1186/s12866-024-03513-z
9. Sivasankari R, Usha B. Reshaping the gut microbiota through lifestyle interventions in women with PCOS: a review. *Indian J Microbiol*. 2022;62 (3):351–363. doi:10.1007/s12088-022-01019-8
10. Li M, Chang Q, Luo Y, et al. The gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones. *Front Cell Dev Biol*. 2024;12:1384233. doi:10.3389/fcell.2024.1384233
11. Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. *Ther Adv Reprod Health*. 2020;14:2633494120911038. doi:10.1177/2633494120911038
12. Somagutta MR, Jain M, Uday U, et al. Novel antidiabetic medications in polycystic ovary syndrome. *Discoveries*. 2022;10(1):e145. doi:10.15190/d.2022.4
13. Fahs D, Salloum D, Nasrallah M, Ghazeeri G. Polycystic ovary syndrome: pathophysiology and controversies in diagnosis. *Diagnostics*. 2023;13 (9). doi:10.3390/diagnostics13091559
14. Huang R, Zheng J, Li S, Tao T, Ma J, Liu W. Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome. *Acta Obstet Gynecol Scand*. 2015;94(5):494–500. doi:10.1111/aogs.12612
15. Amiri M, Tehrani FR, Bidhendi-Yarandi R, Behboudi-Gandevani S, Azizi F, Carmina E. Relationships between biochemical markers of hyperandrogenism and metabolic parameters in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Horm Metab Res*. 2019;51(1):22–34. doi:10.1055/a-0806-8281
16. Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. *Gynecol Endocrinol*. 2010;26(10):736–742. doi:10.3109/09513590.2010.481025
17. Tu P, Bian X, Chi L, et al. Metabolite profiling of the gut microbiome in mice with dietary administration of black raspberries. *ACS Omega*. 2020;5 (3):1318–1325. doi:10.1021/acsomega.9b00237
18. Kurowska P, Mlyczyńska E, Dawid M, et al. Endocrine disruptor chemicals, adipokines and reproductive functions. *Endocrine*. 2022;78 (2):205–218. doi:10.1007/s12020-022-03061-4
19. Lane JM, Wright RO, Eggers S. The interconnection between obesity and executive function in adolescence: the role of the gut microbiome. *Neurosci Biobehav Rev*. 2023;153:105337. doi:10.1016/j.neubiorev.2023.105337
20. Kerstholt M, Netea MG, Joosten LAB. Borrelia burgdorferi hijacks cellular metabolism of immune cells: consequences for host defense. *Ticks Tick Borne Dis*. 2020;11(3):101386. doi:10.1016/j.ttbdis.2020.101386
21. Herman T, Csehely S, Orosz M, et al. Prevalence and association of endocrine disorders in women participating in an in vitro fertilization program Orv Hetil. *Orvosi hetilap*. 2022;163(18):712–719. doi:10.1556/650.2022.32372
22. Gong Z, Yan Z, Liu W, Luo B. Oncogenic viruses and host lipid metabolism: a new perspective. *J Gen Virol*. 2023;104(6). doi:10.1099/jgv.0.001861
23. Salehi S, Allahverdy J, Pourjafar H, Sarabandi K, Jafari SM. Gut microbiota and polycystic ovary syndrome (PCOS): understanding the pathogenesis and the role of probiotics as a therapeutic strategy. *Probiotics Antimicrob Proteins*. 2024;16(5):1553–1565. doi:10.1007/s12602-024-10223-5
24. Liang Z, Di N, Li L, Yang D. Gut microbiota alterations reveal potential gut-brain axis changes in polycystic ovary syndrome. *J Endocrinol Invest*. 2021;44(8):1727–1737. doi:10.1007/s40618-020-01481-5
25. Yang M, Deng H, Zhou S, et al. Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics. *Front Microbiol*. 2024;15:1373077. doi:10.3389/fmicb.2024.1373077
26. Yu Z, Qin E, Cheng S, et al. Gut microbiome in PCOS associates to serum metabolomics: a cross-sectional study. *Sci Rep*. 2022;12(1):22184. doi:10.1038/s41598-022-25041-4
27. Kukaev E, Kirillova E, Tokareva A, et al. Impact of gut microbiota and SCFAs in the pathogenesis of PCOS and the effect of metformin therapy. *Int J Mol Sci*. 2024;25(19):10636. doi:10.3390/ijms251910636
28. Mihajlovic J, Leutner M, Hausmann B, et al. Combined hormonal contraceptives are associated with minor changes in composition and diversity in gut microbiota of healthy women. *Environ Microbiol*. 2021;23(6):3037–3047. doi:10.1111/1462-2920.15517
29. Peker N, Turan G, Ege S, Bademkıran MH, Karaçor T, Ö E. The effect of clomiphene citrate on oxidative stress parameters in polycystic ovarian syndrome. *J Obstet Gynaecol*. 2021;41(1):112–117. doi:10.1080/01443615.2020.1719052
30. Jalil AT, Zair MA, Hanthal ZR, et al. Role of the AMP-activated protein kinase in the pathogenesis of polycystic ovary syndrome. *Indian J Clin Biochem*. 2024;39(4):450–458. doi:10.1007/s12291-023-01139-y
31. Achu Joseph R, Ajitkumar S, Kanakasabapathy Balaji S, Santhanakrishnan M. Evaluation of microbial profile in patients with polycystic ovary syndrome and periodontal disease: a case-control study. *Int J Fertil Steril*. 2023;17(4):248–253. doi:10.22074/ijfs.2023.550187.1272
32. Wang Y, Ma X, Luo J, Wang X, Han L. Expression of serum PSA, nesfatin-1, and AMH in patients with polycystic ovary syndrome. *Cell Mol Biol*. 2022;67(5):57–63. doi:10.14715/cmb/2021.67.5.8
33. Gökçek İ, Uyanık G, Tutar T, Gözer A. Effects of carvacrol on hormonal, inflammatory, antioxidant changes, and ovarian reserve in polycystic ovary syndrome in Wistar rats. *Naunyn Schmiedebergs Arch Pharmacol*. 2024. 10.1007/s00210-024-03588-5
34. Wang Y, Guo L, Jiang J, Wang F, Hardiman PJ, Qu F. Development of 1-2 years offspring born to mothers with polycystic ovary syndrome. *J Coll Physicians Surg Pak*. 2021;31(10):1186–1190. doi:10.29271/jcpsp.2021.10.1186
35. Long BY, Liao X, Liang X. The hypothalamus and pituitary gland regulate reproduction and are involved in the development of polycystic ovary syndrome. *Neuroendocrinology*. 2025;1-26. doi:10.1159/000543877

36. Benham JL, Goldberg A, Teede H, Tay CT. Polycystic ovary syndrome: associations with cardiovascular disease. *Climacteric*. 2024;27(1):47–52. doi:10.1080/13697137.2023.2282689
37. Zhan QY, Xie LX, Wang C. Promoting critical care system and capacity building in pulmonary and critical care medicine subspecialties. *Zhonghua Yi Xue Za Zhi*. 2023;103(40):3149–3151. doi:10.3760/cma.j.cn112137-20230602-00919
38. He FF, Li YM. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review. *J Ovarian Res*. 2020;13(1):73. doi:10.1186/s13048-020-00670-3
39. Singh S, Pal N, Shubham S, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. *J Clin Med*. 2023;12(4). doi:10.3390/jcm12041454
40. Qi X, Yun C, Pang Y, Qiao J. The impact of the gut microbiota on the reproductive and metabolic endocrine system. *Gut Microbes*. 2021;13(1):1–21. doi:10.1080/19490976.2021.1894070
41. Wong W. A gut punch for PCOS. *Sci Signal*. 2024;17(841):eadr0297. doi:10.1126/scisignal.adr0297
42. Gautam R, Maan P, Patel AK, Vasudevan S, Arora T. Unveiling the complex interplay between gut microbiota and polycystic ovary syndrome: a narrative review. *Clin Nutr*. 2024;43(12):199–208. doi:10.1016/j.clnu.2024.10.028
43. Guo H, Luo J, Lin H. Exploration of the pathogenesis of polycystic ovary syndrome based on gut microbiota: a review. *Medicine*. 2023;102(50):e36075. doi:10.1097/MD.0000000000036075
44. Amaro-da-Cruz A, Rubio-Tomás T, Álvarez-Mercado AI. Specific microbiome patterns and their association with breast cancer: the intestinal microbiota as a potential biomarker and therapeutic strategy. *Clin Transl Oncol*. 2025;27(1):15–41. doi:10.1007/s12094-024-03554-w
45. Alsayed AR, Abed A, Khader HA, et al. Molecular accounting and profiling of human respiratory microbial communities: toward precision medicine by targeting the respiratory microbiome for disease diagnosis and treatment. *Int J Mol Sci*. 2023;24(4):4086. doi:10.3390/ijms24044086
46. Pal P, Shastry RP. Exploring the complex role of gut microbiome in the development of precision medicine strategies for targeting microbial imbalance-induced colon cancer. *Folia Microbiol*. 2023;68(5):691–701. doi:10.1007/s12223-023-01085-5
47. Shukla V, Singh S, Verma S, Verma S, Rizvi AA, Abbas M. Targeting the microbiome to improve human health with the approach of personalized medicine: latest aspects and current updates. *Clin Nutr ESPEN*. 2024;63:813–820. doi:10.1016/j.clnesp.2024.08.005
48. Minervini G, Shivakumar S, Ronsivalle V, Franco R, Cicciù M, Marrapodi MM. Microbiological aspects of cancer progression: a systematic review conducted according to the PRISMA 2020 guidelines and the Cochrane handbook for systematic reviews of interventions. *Dent Med Probl*. 2024;61(5):739–746. doi:10.17219/dmp/183712
49. Sahle Z, Engidaye G, Shenkute Gebreyes D, Adenew B, Abebe TA. Fecal microbiota transplantation and next-generation therapies: a review on targeting dysbiosis in metabolic disorders and beyond. *SAGE Open Med*. 2024;12:20503121241257486. doi:10.1177/20503121241257486